Show Notes
What if the future of regenerative medicine isn't just about stem cells—but the biological messages those cells send? In this episode of Peptides Explained, John Garrett sits down with Sanjiv Lal, founder of Cell Factor and co-founder of Regen Therapy, to explore the emerging science of secretomes, cellular communication, and regenerative medicine. Sanjiv shares his personal journey from pharmaceutical sciences and molecular diagnostics to becoming a patient facing significant health challenges. That experience sparked his interest in cell-free regenerative technologies and the biological signaling systems involved in tissue repair, inflammation, and aging. Together, John and Sanjiv explore: Secretome science: What secretomes are and how they differ from stem cells and exosomes.
Cellular communication: How peptides, growth factors, cytokines, and extracellular vesicles influence biological signaling.
Cell Factor: Sanjiv's explanation of the technology, manufacturing process, and potential applications.
Mitochondrial health: The relationship between cellular energy, inflammation, and biological function.
Healthspan vs. lifespan: Why extending healthy, functional years matters as much as extending life.
Peptides and longevity: Sanjiv's personal experience with Cell Factor, SS-31, MOTS-c, and other interventions.
The future of healthcare: The potential role of preventive medicine, personalized diagnostics, and emerging regenerative technologies.
Sanjiv also discusses his own health improvements and his vision for expanding access to regenerative medicine through Regen Therapy and related ventures. The bigger question: Can scientists harness cellular signaling to improve human health, and what clinical evidence will be needed to demonstrate that these approaches are safe and effective? This is a conversation about scientific possibility, innovation, and taking a more active role in long-term health. Learn more: Cell Factor: https://cell.health/ RegenTherapy https://regentherapy.com Important disclaimer: This episode is for educational purposes only and does not constitute medical advice. Cell Factor and the experimental approaches discussed should not be considered proven treatments for kidney disease, diabetes, aging, or other medical conditions. Personal experiences are not controlled clinical evidence. Consult a qualified healthcare professional before making treatment decisions.
More from Peptides Explained
True-Sciences.com Use Code Pep20 for 20% off. A careful look at CJC-1295: the growth-hormone pathway, the distinction between DAC and no-DAC naming, what small human studies measured, the terminated Phase 2 trial, current FDA compounding information, the unproven CJC-1295/ipamorelin combination claims, and WADA's 2026 rules. The evidence supports a hormone effect for the long-acting DAC-modified compound; it does not establish the benefits often marketed for consumer products. Educational content only; not medical advice. Snapshot checked October 19, 2026.
Seed oils may be hiding in more of your everyday foods than you realize. In this episode of Peptides Explained, host John talks with Cherie Calbom, MS—known as the Juice Lady—about seed oils, cooking fats, inflammation, and how to make more informed choices at the grocery store and when dining out.Cherie discusses how common seed oils are processed, why she recommends checking ingredient labels, and which alternatives she uses, including olive oil, avocado oil, coconut oil, ghee, and beef tallow. They also talk about omega-6 and omega-3 balance, cooking with different fats, and practical ways to make food swaps without giving up flavor.The conversation explores the history of seed oils and changing ideas about dietary fat and cholesterol. Cherie shares tips for spotting oils in packaged foods and describes resources for people who want to learn more, including her book The Truth About Seed Oils. Topics include: seed oils, cooking fats, inflammation, omega-6 and omega-3, food labels, nutrition, and healthy cooking.
Eli Lilly is taking legal action against businesses selling products labeled retatrutide. What do the lawsuits actually establish—and what don't they? John Garrett separates pending legal allegations from court findings, reviews the human trial evidence for the investigational triple agonist, and explains why molecular identity, purity, and pharmaceutical equivalence are not interchangeable. We also examine FDA restrictions, consumer safety, and the implications for clinics, vendors, and independent educators. Educational only; not medical or legal advice. Retatrutide is not FDA-approved. Sources: NEJM DOI 10.1056/NEJMoa2301972; FDA unapproved GLP-1 drug concerns; ClinicalTrials.gov NCT05929066 and NCT05882045.
Can peptide biology protect the brain from vascular damage? John follows a question that started with Vesugen into the biology of vascular cognitive impairment—endothelial dysfunction, hypoperfusion, blood-brain-barrier injury, mitochondrial stress, inflammation and neuronal damage. The episode maps Cerebrolysin, SS-31/elamipretide, ARA-290/cibinetide, Semax, Vesugen and GLP-1 receptor agonists onto different points in that cascade, then asks the question that matters: what does the human evidence actually support? Cerebrolysin provides the biggest surprise, with randomized vascular-dementia trials—but still low-certainty evidence. Educational only; not medical advice.
Everyone keeps calling belly fat "visceral fat." That is not how anatomy works. In this crossover episode, John breaks down the difference between visceral and subcutaneous fat, why visceral adipose tissue matters metabolically, how it is actually measured, what waist circumference can and cannot tell you, and what the evidence says about GLP-1 therapies and tesamorelin.